A head‐to‐head comparison of risankizumab and ixekizumab for genital psoriasis: a real‐life, 24‐week, prospective study.

2021 ◽  
Author(s):  
E Sotiriou ◽  
K Bakirtzi ◽  
I Papadimitriou ◽  
A Tsentemeidou ◽  
P Eftychidou ◽  
...  
Keyword(s):  
Prospective Study ◽  
Real Life ◽  
Genital Psoriasis

Incidence and risk factors for dupilumab associated ocular adverse events: a real‐life prospective study

2020 ◽  
Author(s):  
A.T. Touhouche ◽  
M. Cassagne ◽  
E. Bérard ◽  
F. Giordano‐Labadie ◽  
A. Didier ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adverse Events ◽  
Prospective Study ◽  
Real Life

Management of Uncomplicated Acute Appendicitis as Day Case Surgery: Can Outcomes of a Prospective Study Be Reproduced in Real Life?

2019 ◽  
Vol 229 (3) ◽  
pp. 277-285 ◽  
Author(s):  
Charles Sabbagh ◽  
Loréna Masseline ◽  
Gérard Grelpois ◽  
Alexandre Ntouba ◽  
Jeanne Dembinski ◽  
...  
Keyword(s):  
Acute Appendicitis ◽  
Prospective Study ◽  
Real Life ◽  
Day Case ◽  
Day Case Surgery ◽  
Case Surgery ◽  
Uncomplicated Acute Appendicitis ◽  
A Prospective Study

scholarly journals Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study

2010 ◽  
Vol 7 (1) ◽  
pp. 5 ◽  
Author(s):  
Luis F López-Cortés ◽  
Pompeyo Viciana ◽  
Rosa Ruiz-Valderas ◽  
Juan Pasquau ◽  
Josefa Ruiz ◽  
...  
Keyword(s):  
Prospective Study ◽  
Reverse Transcriptase ◽  
Real Life ◽  
Reverse Transcriptase Inhibitors ◽  
Once Daily ◽  
Multicentre Prospective Study

Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population

2019 ◽  
Vol 8 (3) ◽  
pp. 165-178 ◽  
Author(s):  
María Cerdá ◽  
Juan J Cerezo-Manchado ◽  
Erik Johansson ◽  
Fernanda Martínez ◽  
Mariana Fernández ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Prospective Study ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Real Life ◽  
Spanish Population ◽  
Nonvalvular Atrial Fibrillation

PD07-02 PCA3 IN PROSTATE CANCER RISK ASSESSMENT: HOW DOES IT HELP IN REAL LIFE? RESULT OF A 5–YEAR PROSPECTIVE STUDY

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Marine Lesourd ◽  
Jean Baptiste Beauval ◽  
Benjamin Pradere ◽  
Daniel Portalez ◽  
Xavier Gamé ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Prospective Study ◽  
Real Life ◽  
Prostate Cancer Risk ◽  
Cancer Risk Assessment

scholarly journals Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma

Thorax ◽  
2017 ◽  
Vol 73 (8) ◽  
pp. 782-784 ◽  
Author(s):  
Maria del Carmen Vennera ◽  
Carlos Sabadell ◽  
Cesar Picado
Keyword(s):  
Prospective Study ◽  
Asthma Control ◽  
Severe Asthma ◽  
Asthma Exacerbation ◽  
Real Life ◽  
First Year ◽  
Severe Asthma Exacerbation ◽  
Optimal Duration ◽  
Open Prospective Study

Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration of the treatment remains unclear. In an open prospective study, we sought to assess the persistence of response in subjects withdrawing from omalizumab treatment. We evaluated 49 patients who voluntarily accepted to discontinue omalizumab treatment after 6 years of therapy. Asthma relapse was defined as any severe asthma exacerbation associated with loss of asthma control. Twelve patients relapsed in the first year of follow-up, and 7 within 13 and 48 months. These results suggest that the effects of 6 years of omalizumab may persist after discontinuation of therapy in 60% of patients for at least 4 years.

scholarly journals An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis

2021 ◽  
Author(s):  
Marietta Iacucci ◽  
Samuel C.L. Smith ◽  
Alina Bazarova ◽  
Uday N. Shivaji ◽  
Pradeep Bhandari ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Prospective Study ◽  
Real Life ◽  
International Multicenter

scholarly journals High performances of a novel antigen detection test on nasopharyngeal specimens for SARS-CoV-2 infection diagnosis: a prospective study

2020 ◽  
Author(s):  
Laura Courtellemont ◽  
jerome Guinard ◽  
Clemence Guillaume ◽  
Susanna Giache ◽  
Vincent Rzepecki ◽  
...  
Keyword(s):  
Prospective Study ◽  
Large Scale ◽  
Quantitative Polymerase Chain Reaction ◽  
Real Life ◽  
Rapid Test ◽  
Threshold Value ◽  
Public Health Issue ◽  
Nasopharyngeal Swab ◽  
Specificity And Sensitivity ◽  
Asymptomatic Patients

Introduction The SARS-CoV-2 pandemic has become a major public health issue worldwide. Developing and evaluating rapid and easy-to-perform diagnostic tests is an absolute priority. The current prospective study was designed to assess diagnostic performances of an antigen-based rapid detection test (COVID-VIRO) in a real-life setting. Methods Two nasopharyngeal specimens of symptomatic or asymptomatic adult patients hospitalized in the Infectious Diseases Department or voluntarily accessing the COVID-19 Screening Department of the Regional Hospital of Orleans, France, were concurrently collected. COVID VIRO diagnostic specificity and sensitivity were assessed in comparison to real-time reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) results. A subgroup of patients underwent an additional oropharyngeal and/or a saliva swab for rapid testing. Results 121 patients already having a confirmed infection and 127 patients having no evidence of recent or ongoing infection were enrolled, for a total of 248 couple of nasopharyngeal swab specimens. Overall COVID-VIRO sensitivity was 96.7% (IC: 93.5%-99.9%). In asymptomatic patients, patients having symptoms for more than 4 days and those having a RT-qPCR Cycle threshold value >32, sensitivity was of 100%, 95.8% and 96.9% respectively. The concordance between RT-qPCR and COVID VIRO rapid test was 100% for the 127 patients with no SARS-CoV-2 infection. Conclusion COVID-VIRO test had 100% specificity and above 95% sensitivity, better than WHO recommendations (specificity ≥97-100%, sensitivity ≥80%). These rapid tests are particularly interesting for large-scale screening in Emergency Department, low resource settings and airports.

Sign in / Sign up

Export Citation Format

Share Document